NCT06834035View on ClinicalTrials.gov

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

March 6, 2026

Study Completion Date

March 6, 2026

Conditions
Epidermolysis BullosaEpidermolysis Bullosa AcquisitaDystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa
Interventions
BIOLOGICAL

Immunoglobulin G

Purified IgG from human serum, delivered via IV

Trial Locations (1)

94163

RECRUITING

Stanford University, Redwood City

All Listed Sponsors
collaborator

Epidermolysis Bullosa Research Partnership

OTHER_GOV

lead

M. Peter Marinkovich

OTHER